These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15750036)

  • 1. Safety and efficacy of glycopeptide antibiotics.
    Finch RG; Eliopoulos GM
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii5-13. PubMed ID: 15750036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
    Printsevskaya SS; Pavlov AY; Olsufyeva EN; Mirchink EP; Preobrazhenskaya MN
    J Med Chem; 2003 Mar; 46(7):1204-9. PubMed ID: 12646030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vancomycin resistance among strains of Enterococcus faecium].
    Sacha P; Wieczorek P; Jakoniuk P
    Przegl Lek; 2008; 65(5):229-32. PubMed ID: 18853647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of resistance to glycopeptide antibiotics in staphylococci.
    Biavasco F; Giovanetti E; Varaldo PE
    J Chemother; 1991 Jan; 3 Suppl 1():166-8. PubMed ID: 12041756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of spontaneous resistance to glycopeptide antibiotics in staphylococcal populations.
    Biavasco F; Montanari MP; Facinelli B; Varaldo PE
    J Chemother; 1989 Jul; 1(4 Suppl):389-90. PubMed ID: 16312453
    [No Abstract]   [Full Text] [Related]  

  • 12. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
    Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
    Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiological profile of teicoplanin.
    Covelli I; Nani E
    J Chemother; 1991 Jan; 3 Suppl 1():39-42. PubMed ID: 12041783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
    Leonard SN; Rybak MJ
    Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalbavancin: a novel lipoglycopeptide antibacterial.
    Pope SD; Roecker AM
    Pharmacotherapy; 2006 Jul; 26(7):908-18. PubMed ID: 16803423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing therapy for vancomycin-resistant enterococci (VRE).
    Linden PK
    Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vancomycin and teicoplanin: differential aspects].
    Cobo J
    Enferm Infecc Microbiol Clin; 1995 Dec; 13(10):600-10. PubMed ID: 8808477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.